Brokers Offer Predictions for Liquidia FY2024 Earnings

Liquidia Co. (NASDAQ:LQDA) – Equities research analysts at Lifesci Capital increased their FY2024 EPS estimates for Liquidia in a research note issued to investors on Wednesday, November 13th. Lifesci Capital analyst C. Jubinville now anticipates that the company will post earnings per share of ($1.48) for the year, up from their previous estimate of ($1.57). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. Lifesci Capital also issued estimates for Liquidia’s Q4 2024 earnings at ($0.36) EPS.

LQDA has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. BTIG Research lowered their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, Scotiabank started coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Price Performance

NASDAQ LQDA opened at $9.82 on Monday. Liquidia has a 1-year low of $6.33 and a 1-year high of $16.99. The stock has a market capitalization of $831.14 million, a price-to-earnings ratio of -6.02 and a beta of 0.21. The business’s fifty day moving average price is $10.52 and its 200-day moving average price is $11.47.

Insiders Place Their Bets

In other news, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the transaction, the insider now owns 204,857 shares of the company’s stock, valued at $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Caligan Partners Lp bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were acquired at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. This trade represents a 2.19 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 21,551 shares of company stock worth $236,021 over the last three months. 30.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently modified their holdings of the stock. Swiss National Bank bought a new stake in Liquidia in the 1st quarter valued at $1,325,000. Sei Investments Co. bought a new stake in shares of Liquidia in the first quarter worth about $531,000. Vanguard Group Inc. lifted its position in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after buying an additional 43,352 shares in the last quarter. American International Group Inc. boosted its stake in Liquidia by 5.2% during the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock valued at $366,000 after buying an additional 1,215 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Liquidia during the 1st quarter valued at approximately $1,755,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).